Puma Biotechnology falls more than 20%
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Former Puma Biotechnology exec is accused of making $1.2 million from insider trading - Los Angeles Times
Why Shares of Puma Biotechnology Rose This Week | The Motley Fool
Federal Jury Awards Puma Biotechnology Investors Damages in Securities Class-Action Verdict - Los Angeles Business Journal
Puma Biotechnology, Inc. (PBYI) Company Information - Simply Wall St
Articles with Puma Biotechnology | page 2
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Exhibitor Puma Biotechnology 11-6 - Scripps CME Connection
Puma Biotechnology reports interim SUMMIT results for neratinib | Drug Discovery News
Puma Biotechnology (PBYI) - 5 Price Charts 2012-2023 (History)
Puma Biotechnology Inc (PBYI) Stock Price & Performance 2023
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotechnology
Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology - Crunchbase Company Profile & Funding
Can Puma Biotechnology Inc (PBYI) Stock Rise to the Top of Healthcare Sector Tuesday?
Puma Biotechnology
PharmaShots - Incisive news in 3 shots on Twitter: "Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer https://t.co/KKTvnp68jJ https://t.co/LR02TGd4oT" / Twitter
Former Puma Biotechnology Executive Sentenced to More than Two Years in Prison for Insider Trading | BioSpace
Fillable Online Puma biotechnology, inc. form s-1/a - Biotech Due Diligence Fax Email Print - pdfFiller
Puma Biotechnology Surging
Puma Biotechnology
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
